PDX Pharma was awarded a new grant from NCI

We are pleased to share that PDX Pharmaceuticals has received a $250,000 SBIR Commercialization Readiness Program (CRP) grant (SB1CA287735) from the National Cancer Institute (NCI) to advance ARAC-02™, our next-gen immunotherapy for non-small cell lung cancer (NSCLC). This funding supports intellectual property (IP) protection of our core nanotechnology (Pdx-NP™) and ARAC-02™, as well as the initiation of a GMP-compliant manufacturing campaign. The goal is to enhance commercialization readiness and prepare for clinical trials. Huge congrats to our team, and a big thank you to the NCI for their continued support!

Read here for more information.

**Research was supported by the National Cancer Institute of the National Institutes of Health under Award Number SB1CA287735. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.